Table 1 Clinicopathologic characteristics of studied population (n = 123)
n(%) | ||
|---|---|---|
Age(years) | ||
Mean ± SD | 69.05 ± 8.68 | |
Mean follow up time (months) | 21.67 + 12.56 | |
Age Groups | ||
≤70 years | 77(62.6) | |
> 70 years | 46(37.4) | |
Tumor quantification (%) | ||
Mean ± SD | 49.83 ± 30.53 | |
Groups | ||
< 10% | 23(18.7) | |
10–50% | 35(28.5) | |
> 50% | 65(52.8) | |
Total gleason score | 6 | 39(31.7) |
7 | 29(23.6) | |
8 | 27(22) | |
9 | 28(22.8) | |
WHO grade group | Grade 1 | 39(31.7) |
Grade 2 | 25(20.3) | |
Grade 3 | 4(3.3) | |
Grade 4 | 27(22) | |
Grade 5 | 28(22.8) | |
Perineural invasion | Present | 46(37.4) |
Absent | 77(62.6) | |
Lymphovascular invasion | Present | 3(2.4) |
Absent | 120 (97.6) | |
Extraprostatic extension | Present | 7(5.7) |
Absent | 116(94.3) | |
Seminal vesicle invasion | Present | 4(3.3) |
Absent | 119(96.7) | |
Specimen type | Radical prostatectomy | 18(14.6) |
TURP | 105(85.4) | |
Recurrence duration (months) | 9.39 ± 3.22 | |
Recurrence | Yes | 33(26.8) |
No | 90(73.2) | |
EFGR expression | Positive | 23(18.7) |
Negative | 100(81.3) | |
Her2 neu | Positive | 28(22.8) |
Negative | 95(77.2) | |